Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Versus Standard of Care in Major Hepatectomy
NCT07507643Phase 3Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylprednisolone in postoperative complications (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: 30-day all-cause morbidity. Started Mar 2026; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
postoperative complications
Beyond the preview
Go deeper on NCT07507643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507643.